Itolizumab

Summary

Itolizumab (CHEMBL1743033) is a phase-3 clinical-stage antibody targeting CD6; indicated across 7 conditions including severe acute respiratory syndrome and graft versus host disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (CD6)
• Indications: 7 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743033
Name	Itolizumab
Type	Antibody
Max phase	3

Also known as: BMAB-600, Bmab 600, EQ-001, EQ001, Itolizumab, T1h, ITOLIZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CD6	CD6	Binding	7.22	1.5%	P30203

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CD6.

Dominant GO biological processes

GO term	Targets
immunological synapse formation	1
adaptive immune response	1
acute inflammatory response to antigenic stimulus	1
heterophilic cell-cell adhesion	1
lipopolysaccharide-mediated signaling pathway	1
response to lipopolysaccharide	1
positive regulation of T cell proliferation	1
innate immune response	1
positive regulation of cytokine production involved in inflammatory response	1
immune system process	1
cell adhesion	1

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
graft versus host disease	3	MONDO:0013730	MONDO:0013730
asthma	1	MONDO:0004979	MONDO:0004979
autoimmune disease	1	MONDO:0007179	EFO:0005809
dermatomyositis	1	MONDO:0016367	EFO:0000398
acute respiratory distress syndrome	1	MONDO:0006502	EFO:1000637

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	5
PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04605926	PHASE3	WITHDRAWN	A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
NCT05263999	PHASE3	TERMINATED	A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
NCT03763318	PHASE1/PHASE2	COMPLETED	A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
NCT02649270	PHASE1	TERMINATED	Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis
NCT04007198	PHASE1	COMPLETED	A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma
NCT05823675	PHASE1	UNKNOWN	Safety and Clinical Activity of Itolizumab in aGVHD
NCT05978544	PHASE1	UNKNOWN	Safety and Preliminary Clinical Activity of Itolizumab in ARDS
NCT05986162	PHASE1	UNKNOWN	Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).